ovarian cancer
Showing NaN - NaN of 91
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
Minimal Residual Disease, KRAS G12D, KRAS G12R Trial in United States (ELI-002 2P)
Recruiting
- Minimal Residual Disease
- +11 more
- ELI-002 2P
-
Duarte, California
- +10 more
Jan 18, 2023
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Ovarian Cancer Trial in Worldwide (VS-6766, VS-6766 and Defactinib)
Recruiting
- Low Grade Ovarian Serous Adenocarcinoma
- Ovarian Cancer
- avutometinib (VS-6766)
- avutometinib (VS-6766) and Defactinib
-
Scottsdale, Arizona
- +46 more
Dec 29, 2022
Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics Trial in Worldwide (AZD5363)
Active, not recruiting
- Advanced Solid Malignancy
- +13 more
-
Los Angeles, California
- +33 more
Dec 22, 2022
Platinum Sensitive Ovarian Cancer, Ovarian Cancer Trial in United States (FRa peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF)
Terminated
- Platinum Sensitive Ovarian Cancer
- Ovarian Cancer
- FRα peptide plus Adjuvant (GM-CSF)
- Adjuvant (GM-CSF) Alone
-
Birmingham, Alabama
- +17 more
Nov 21, 2022
Melanoma, Prostate Cancer, Ovarian Cancer Trial in United States (Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or
Active, not recruiting
- Melanoma
- +8 more
- Pegilodecakin
- +9 more
-
Los Angeles, California
- +9 more
Nov 15, 2022
Validation for Early Cancer Detection and Minimal Residual
Recruiting
- Brain Cancer
- +19 more
-
Duarte, California
- +6 more
Nov 10, 2022
Breast Cancer, Colorectal Cancer, Ovarian Cancer Trial in United States (ATRC-101, Pembrolizumab, Pegylated liposomal
Recruiting
- Breast Cancer
- +15 more
- ATRC-101
- +2 more
-
Phoenix, Arizona
- +10 more
Sep 28, 2022
Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer Trial in United States (navicixizumab+paclitaxel,
Recruiting
- Colorectal Cancer
- +3 more
- navicixizumab+paclitaxel
- +2 more
-
Hot Springs, Arkansas
- +5 more
Aug 9, 2022
Urinary Bladder Cancer, Melanoma, Head Neck Cancer Trial in Canada, United States (Autologous genetically modified MAGE-A4?¹º³²T
Active, not recruiting
- Urinary Bladder Cancer
- +9 more
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
-
Miami, Florida
- +10 more
Aug 9, 2022
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Datopotamab deruxtecan
Not yet recruiting
- Endometrial Cancer
- +4 more
- Datopotamab deruxtecan (Dato-DXd)
- +8 more
-
Los Angeles, California
- +52 more
Aug 3, 2022
NSCLC, Renal Cell Cancer, Colorectal Cancer Trial in Australia, United States (CPI-006, CPI-006 + ciforadenant, CPI-006 +
Active, not recruiting
- Non-Small Cell Lung Cancer
- +12 more
- CPI-006
- +2 more
-
Tucson, Arizona
- +26 more
Aug 1, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Worldwide (Mirvetuximab soravtansine)
Recruiting
- Ovarian Cancer
- +2 more
- Mirvetuximab soravtansine
-
Anchorage, Alaska
- +55 more
Jul 25, 2022
Ovarian Cancer Trial in Worldwide (Chemotherapy + avelumab followed by avelumab + talazoparib, Chemotherapy followed by
Completed
- Ovarian Cancer
- Chemotherapy + avelumab followed by avelumab + talazoparib
- +2 more
-
Phoenix, Arizona
- +71 more
Jul 21, 2022
Advanced Malignant Tumor, Breast Cancer, Ovarian Cancer Trial in United States (AMXI-5001:Dose Escalation Phase I,
Recruiting
- Advanced Malignant Neoplasm
- +5 more
- AMXI-5001:Dose Escalation Phase I
- AMXI-5001:Dose Expansion Phase II
-
Phoenix, Arizona
- +7 more
Jul 18, 2022
NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +5 more
- CART-TnMUC1
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 18, 2022